WO2007042289A3 - Nanobodies™ and polypeptides against egfr and igf-ir - Google Patents

Nanobodies™ and polypeptides against egfr and igf-ir Download PDF

Info

Publication number
WO2007042289A3
WO2007042289A3 PCT/EP2006/009840 EP2006009840W WO2007042289A3 WO 2007042289 A3 WO2007042289 A3 WO 2007042289A3 EP 2006009840 W EP2006009840 W EP 2006009840W WO 2007042289 A3 WO2007042289 A3 WO 2007042289A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanobodies
polypeptides
igf
nucleic acids
host cells
Prior art date
Application number
PCT/EP2006/009840
Other languages
French (fr)
Other versions
WO2007042289A2 (en
Inventor
Toon Laeremans
Haard Hans De
Hendricus Renerus J Hoogenboom
Original Assignee
Ablynx Nv
Toon Laeremans
Haard Hans De
Hendricus Renerus J Hoogenboom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv, Toon Laeremans, Haard Hans De, Hendricus Renerus J Hoogenboom filed Critical Ablynx Nv
Priority to JP2008534933A priority Critical patent/JP2009511032A/en
Priority to US12/083,406 priority patent/US20090252681A1/en
Priority to CA002624781A priority patent/CA2624781A1/en
Priority to AU2006301426A priority patent/AU2006301426A1/en
Priority to EP06792421A priority patent/EP1934259A2/en
Publication of WO2007042289A2 publication Critical patent/WO2007042289A2/en
Publication of WO2007042289A3 publication Critical patent/WO2007042289A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to polypeptides and Nanobodies against Epidermal Growth Factor Receptor (EGFR) and/or Insulin Growth Factor-I Receptor (IGF-IR). The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such Nanobodies, polypeptides, nucleic acids and/or host cells; and to uses of such Nanobodies, polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
PCT/EP2006/009840 2005-10-11 2006-10-11 Nanobodies™ and polypeptides against egfr and igf-ir WO2007042289A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2008534933A JP2009511032A (en) 2005-10-11 2006-10-11 Nanobodies and polypeptides for EGFR and IGF-IR
US12/083,406 US20090252681A1 (en) 2005-10-11 2006-10-11 Nanobodies and Polypeptides Against EGFR and IGF-IR
CA002624781A CA2624781A1 (en) 2005-10-11 2006-10-11 Nanobodies tm and polypeptides against egfr and igf-ir
AU2006301426A AU2006301426A1 (en) 2005-10-11 2006-10-11 NanobodiesTM and polypeptides against EGFR and IGF-IR
EP06792421A EP1934259A2 (en) 2005-10-11 2006-10-11 Nanobodies and polypeptides against egfr and igf-ir

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72593905P 2005-10-11 2005-10-11
US60/725,939 2005-10-11

Publications (2)

Publication Number Publication Date
WO2007042289A2 WO2007042289A2 (en) 2007-04-19
WO2007042289A3 true WO2007042289A3 (en) 2007-10-04

Family

ID=37837037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009840 WO2007042289A2 (en) 2005-10-11 2006-10-11 Nanobodies™ and polypeptides against egfr and igf-ir

Country Status (6)

Country Link
EP (1) EP1934259A2 (en)
JP (1) JP2009511032A (en)
CN (1) CN101321784A (en)
AU (1) AU2006301426A1 (en)
CA (1) CA2624781A1 (en)
WO (1) WO2007042289A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CA2588106A1 (en) * 2007-05-18 2008-11-18 Nrc - Institute For Biological Sciences Single-domain antibodies and heavy chain antibody against egfr and uses thereof
US20110282033A1 (en) * 2007-05-24 2011-11-17 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
CA2687903C (en) * 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
AU2008328781A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CN102089325A (en) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2439212B1 (en) 2008-05-02 2016-12-21 Novartis AG Improved fibronectin-based binding molecules and uses thereof
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
HUE042919T2 (en) 2008-12-19 2019-07-29 Ablynx Nv Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
CN104447995A (en) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
EP2417163B1 (en) 2009-04-10 2019-02-27 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
LT2805731T (en) 2009-09-03 2019-02-11 Ablynx N.V. Stable formulations of polypeptides and uses thereof
ES2691717T3 (en) 2009-10-30 2018-11-28 Novartis Ag Universal libraries of the binding domain of the inferior side of type III fibronectin type III
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
MX350399B (en) * 2009-12-18 2017-09-06 Novozymes Inc Methods for producing polypeptides in protease-deficient mutants of trichoderma.
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
KR20130080790A (en) 2010-05-20 2013-07-15 아블린쓰 엔.브이. Biological materials related to her3
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
CN102153650B (en) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 Anti-EGFR (epidemic growth factor receptor) humanized antibody L2-H3 and coding gene and application thereof
CA2831415A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
EP2714736A1 (en) 2011-05-27 2014-04-09 Ablynx N.V. Inhibition of bone resorption with rankl binding peptides
CN102321175B (en) * 2011-09-21 2013-08-07 天津胜发生物技术有限公司 Nano-antibody or polypeptide aiming at breast cancer Her2/new
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
CN106046161B (en) 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 Biological substance relevant to C-Met
TW201843172A (en) * 2012-06-25 2018-12-16 美商再生元醫藥公司 Anti-egfr antibodies and uses thereof
WO2014010758A1 (en) 2012-07-13 2014-01-16 学校法人帝京平成大学 Anti-tumour agent, marker for tumour detection, and oral vaccine agent
AU2013372026B2 (en) 2013-01-03 2018-11-08 Merck Patent Gmbh Method for producing secretable antibodies by expression in saccharomyces cerevisiae
EP3049439B1 (en) 2013-09-26 2019-12-25 Ablynx N.V. Bispecific nanobodies
EA035472B1 (en) * 2014-03-06 2020-06-22 Нэшнл Рисеч Каунсил Оф Канада Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
EA035517B1 (en) * 2014-03-06 2020-06-29 Нэшнл Рисеч Каунсил Оф Канада Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
CN106559993B (en) * 2014-03-06 2020-12-15 加拿大国家研究委员会 Insulin-like growth factor 1 receptor specific antibodies and uses thereof
RU2016141385A (en) 2014-03-24 2018-04-28 Дженентек, Инк. CANCER TREATMENT WITH C-MET ANTAGONISTS AND THEIR CORRELATION WITH HGF EXPRESSION
US10118967B2 (en) 2014-10-21 2018-11-06 Ablynx N.V. Methods for treating rheumatoid arthritis by administering IL-6 receptor antibodies
KR101679245B1 (en) 2014-12-09 2016-11-25 전남대학교산학협력단 A composition for diagnosing or imaging cancer targeting epidermal growth factor receptor
US11426468B2 (en) 2014-12-19 2022-08-30 Ablynx N.V. Cysteine linked nanobody dimers
CN106854244B (en) * 2015-12-09 2020-05-22 南京英瀚斯生物科技有限公司 Nano antibody aiming at HER3 and clinical application thereof
JP7030109B2 (en) * 2016-09-14 2022-03-04 テネオバイオ， インコーポレイテッド CD3 binding antibody
CN106492216A (en) * 2016-10-28 2017-03-15 山西纳安生物科技有限公司 Nano antibody drug-delivery preparation system and preparation method and application through exocuticle in incidence
WO2019016237A1 (en) * 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
CN109996872A (en) * 2017-07-20 2019-07-09 深圳普瑞金生物药业有限公司 A kind of EGFR single domain antibody CART and its application for treating tumour
IL302614A (en) 2017-09-08 2023-07-01 Maverick Therapeutics Inc Constrained conditionally activated binding proteins
CA3085572A1 (en) * 2017-12-14 2019-06-20 Abl Bio Inc. Bispecific antibody to a-syn/igf1r and use thereof
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
CA3090321A1 (en) * 2018-02-05 2019-08-08 Stichting Vu Inverse agonistic anti-us28 antibodies
CN112457404B (en) * 2018-09-27 2022-08-12 暨南大学 Anti-human EGFR nano antibody and application
CN114390938A (en) 2019-03-05 2022-04-22 武田药品工业有限公司 Constrained conditionally activated binding proteins
CN114096556A (en) * 2019-07-10 2022-02-25 南洋理工大学 Epidermal Growth Factor Receptor (EGFR) ligands
CN111171151B (en) * 2019-12-26 2021-09-14 佛山汉腾生物科技有限公司 anti-EGFR (epidermal growth factor receptor) nano antibody and application thereof
CN112375135B (en) * 2020-07-06 2022-12-23 上海大学 Artificial epidermal growth factor, designed polypeptide and application thereof
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
CN112646034B (en) * 2020-12-25 2022-06-24 暨南大学 Affinity maturation binding protein of EGFR (epidermal growth factor receptor) and application thereof
CN112646035B (en) * 2020-12-25 2022-06-24 暨南大学 Affinity maturation binding protein of EGFR (epidermal growth factor receptor) and application
CN117980326A (en) 2021-07-14 2024-05-03 2赛文缇生物公司 Engineered T cell receptors fused to binding domains from antibodies
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
CA3232216A1 (en) * 2021-10-18 2023-04-27 Tavotek Biotherapeutics (Hong Kong) Limited Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
WO2023143484A1 (en) * 2022-01-29 2023-08-03 明慧医药（杭州）有限公司 Antigen-binding protein and use thereof
CN117343194B (en) * 2022-02-09 2024-03-05 青岛大学附属医院 Targeting PD-L1/HSA/CCL5 trispecific nano-antibody, derivative thereof and application thereof
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
WO2024109949A1 (en) * 2022-11-25 2024-05-30 明慧医药（杭州）有限公司 Anti-tumor compound and use thereof
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005044858A1 (en) * 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005044858A1 (en) * 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELS CONRATH K ET AL: "Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 10, 9 March 2001 (2001-03-09), pages 7346 - 7350, XP002248402, ISSN: 0021-9258 *
LU D ET AL: "Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 4, 23 January 2004 (2004-01-23), pages 2856 - 2865, XP002316541, ISSN: 0021-9258 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 79, March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1934259A2 (en) 2008-06-25
CN101321784A (en) 2008-12-10
WO2007042289A2 (en) 2007-04-19
CA2624781A1 (en) 2007-04-19
AU2006301426A1 (en) 2007-04-19
JP2009511032A (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2007042289A3 (en) Nanobodies™ and polypeptides against egfr and igf-ir
IL250946B (en) Nanobodies tm against tumor necrosis factor-alpha
WO2009068627A3 (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2008066752A3 (en) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2006122825A3 (en) Single domain vhh antibodies against von willebrand factor
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
WO2008074839A3 (en) Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008119566A3 (en) Cross-species-specific bispecific binders
WO2008025516A3 (en) Tnf superfamily fusion proteins
WO2008119565A3 (en) Cross-species-specific binding domain
WO2008005470A3 (en) Polypeptides that bind membrane proteins

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680044968.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006792421

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006301426

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2624781

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008534933

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12083406

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3070/DELNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006301426

Country of ref document: AU

Date of ref document: 20061011

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006301426

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006792421

Country of ref document: EP